ストックスクリーナーアプリを入手
4.32
0.69%
-0.03
アフターアワーズ：
4.36
0.04
+0.93%
前日終値:
$4.35
開ける：
$4.35
24時間の取引高:
90,442
Relative Volume:
0.49
時価総額：
$142.20M
収益：
-
当期純損益:
$-12.48M
株価収益率:
-11.08
EPS:
-0.39
ネットキャッシュフロー:
$-7.93M
1週間 パフォーマンス:
+5.37%
1か月 パフォーマンス:
+4.35%
6か月 パフォーマンス:
+72.80%
1年 パフォーマンス:
+34.16%
1日の値動き範囲:
$4.1511
$4.38
1週間の範囲:
$4.0865
$4.59
52週間の値動き範囲:
$2.07
$4.98
Anixa Biosciences Inc Stock (ANIX) Company Profile
名前
Anixa Biosciences Inc
セクター
電話
408-708-9808
住所
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
ANIX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
4.32 | 143.19M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-21 | 開始されました | Maxim Group | Buy |
| 2022-12-23 | 開始されました | Chardan Capital Markets | Buy |
| 2021-04-12 | 開始されました | H.C. Wainwright | Buy |
Anixa Biosciences Inc (ANIX) 最新ニュース
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Zacks Research - MarketBeat
Is Anixa Biosciences Inc. stock a top momentum playGold Moves & Precise Entry and Exit Recommendations - newser.com
Can Anixa Biosciences Inc. (CY71) stock sustain double digit ROEWeekly Loss Report & Weekly Watchlist of Top Performers - newser.com
How geopolitical risks impact Anixa Biosciences Inc. (CY71) stockWeekly Trade Recap & High Return Trade Guides - newser.com
Why Anixa Biosciences Inc. stock is recommended by analysts2025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
How risky is Anixa Biosciences Inc. (CY71) stock compared to peersM&A Rumor & Fast Entry High Yield Stock Tips - newser.com
Intraday pattern recognizer results for Anixa Biosciences Inc.July 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
Anixa Biosciences Inc. stock prediction for this week2025 Bull vs Bear & Daily Volume Surge Signals - newser.com
Can Anixa Biosciences Inc. (CY71) stock resist broad market declinesPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Will Anixa Biosciences Inc. stock benefit from commodity pricesWeekly Trend Recap & Consistent Profit Alerts - newser.com
Backtesting results for Anixa Biosciences Inc. trading strategies2025 Key Lessons & Breakout Confirmation Alerts - newser.com
Can Anixa Biosciences Inc. (CY71) stock sustain revenue momentumJuly 2025 Intraday Action & AI Enhanced Execution Alerts - newser.com
Will Anixa Biosciences Inc. (CY71) stock outperform foreign stocksPortfolio Profit Report & Fast Moving Stock Watchlists - newser.com
What momentum indicators show for Anixa Biosciences Inc. stock - newser.com
Anixa Biosciences Inc (NASDAQ:ANIX) Receives $9.00 Average PT from Analysts - Defense World
Will Anixa Biosciences Inc. stock maintain growth storyFed Meeting & Accurate Entry/Exit Alerts - newser.com
Anixa Biosciences (ANIX) Price Target Increased by 11.11% to 10.20 - Nasdaq
WHO approves name for Anixa’s ovarian cancer CAR-T therapy By Investing.com - Investing.com Nigeria
How Anixa Biosciences Inc. stock reacts to oil pricesRate Hike & AI Powered Buy and Sell Recommendations - newser.com
Anixa Biosciences (ANIX) Unveils New Name for Ovarian Cancer The - GuruFocus
WHO approves name for Anixa’s ovarian cancer CAR-T therapy - Investing.com
Anixa Biosciences Inc (ANIX) 財務データ
収益
当期純利益
現金流量
EPS
Anixa Biosciences Inc (ANIX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
0.54%
1.95%
大文字化:
|
ボリューム (24 時間):